{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:19Z","timestamp":1793761039800,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105281","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:51:26Z","timestamp":1773589886000},"page":"105281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology"],"prefix":"10.1016","volume":"222","author":[{"given":"Michael J.","family":"Janes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layne G.","family":"Bruton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105281_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105281_bib2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105281_bib3","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2026.105281_bib5","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.11504","article-title":"Yescarta: a new era for non-hodgkin lymphoma patients","author":"AlDallal","year":"2020","journal-title":"Cureus 12 e11504"},{"key":"10.1016\/j.critrevonc.2026.105281_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.omtm.2023.05.015","article-title":"Medicaid coverage practices for approved gene and cell therapies: existing barriers and proposed policy solutions","volume":"29","author":"Allen","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.critrevonc.2026.105281_bib7","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.critrevonc.2026.105281_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib9","unstructured":"Association of Cancer Care Centers, 2024. The Economics of CAR T\u2011Cell Therapy: Bringing CAR T\u2011Cell Therapy to Community Oncology [WWW Document]. Assoc. Cancer Care Cent. URL \u3008https:\/\/www.accc-cancer.org\/docs\/projects\/car-t-cell-therapies\/the-economics-of-car-t-cell-therapy.pdf\u3009 (accessed 7.17.25)."},{"key":"10.1016\/j.critrevonc.2026.105281_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18773\/austprescr.2023.011","article-title":"Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia","volume":"46","author":"Australian Prescriber","year":"2023","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.critrevonc.2026.105281_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) \u2013 an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105281_bib12","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted, MAGE-A4\u2013positive unresectable or metastatic synovial sarcoma after prior chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105281_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib14","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and t-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105281_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70726","article-title":"CAR-T cell manufacturing for hematological and solid tumors: from the preclinical to clinical point of view","volume":"14","author":"Capolla","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2026.105281_bib16","article-title":"High cost of chimeric antigen receptor t-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2026.105281_bib17","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105281_bib18","doi-asserted-by":"crossref","first-page":"kae059","DOI":"10.1093\/jncics\/pkae059","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.critrevonc.2026.105281_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105281_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1384600","article-title":"The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy","volume":"14","author":"Jacobs","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105281_bib22","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105281_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib25","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105281_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105281_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105281_bib28","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","article-title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","volume":"9","author":"Lust","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105281_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jha2.312","article-title":"Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician\u2019s choice of therapy in the flatiron health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma","volume":"3","author":"Martin","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.critrevonc.2026.105281_bib30","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3324\/haematol.2022.280482","volume":"108","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105281_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2026.105281_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor t-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pr."},{"key":"10.1016\/j.critrevonc.2026.105281_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105281_bib35","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"Vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105281_bib37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105281_bib38","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105281_bib39","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib41","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s12325-024-02822-z","article-title":"Matching-adjusted indirect comparison of brexucabtagene autoleucel (ZUMA-2) and pirtobrutinib (BRUIN) in patients with relapsed\/refractory mantle cell lymphoma previously treated with a covalent bruton tyrosine kinase inhibitor","volume":"41","author":"Salles","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105281_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib43","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/bjh.19439","article-title":"Sequence not salvage","volume":"204","author":"Sborov","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2021.2010069","article-title":"Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed\/refractory large B-cell lymphomas: an indirect treatment comparison","volume":"63","author":"Schuster","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105281_bib45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed\/refractory adult B-cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2026.105281_bib46","first-page":"17","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA. Cancer J. Clin"},{"key":"10.1016\/j.critrevonc.2026.105281_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104751","article-title":"Revolutionizing immunotherapy: the next frontier in CAR T-cell engineering","volume":"211","author":"Suchiita","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.critrevonc.2026.105281_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib50","unstructured":"U.S. Food and Drug Administration, 2025. Approved Cellular and Gene Therapy Products [WWW Document]. FDA. URL \u3008https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products\u3009 (accessed 6.12.25)."},{"key":"10.1016\/j.critrevonc.2026.105281_bib51","unstructured":"U.S. Food and Drug Administration, 2024. AUCATZYL approval [WWW Document]. FDA. URL \u3008https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl\u3009 (accessed 6.12.25)."},{"key":"10.1016\/j.critrevonc.2026.105281_bib52","unstructured":"U.S. Food and Drug Administration, 2022. CARVYKTI approval [WWW Document]. FDA. URL \u3008https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti\u3009 (accessed 6.12.25)."},{"key":"10.1016\/j.critrevonc.2026.105281_bib53","series-title":"ABECMA (idecabtagene vicleucel) approval [WWW Document]","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.critrevonc.2026.105281_bib54","series-title":"BREYANZI (lisocabtagene maraleucel) approval [WWW Document]","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.critrevonc.2026.105281_bib55","series-title":"TECARTUS approval [WWW Document]","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.critrevonc.2026.105281_bib56","series-title":"KYMRIAH approval [WWW Document]","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105281_bib57","series-title":"YESCARTA approval [WWW Document]","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105281_bib58","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2147\/CMAR.S163225","article-title":"Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel","volume":"11","author":"Viardot","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105281_bib59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105281_bib61","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105281_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician\u2019s choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma","volume":"42","author":"Weisel","year":"2022","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.critrevonc.2026.105281_bib63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:36:28Z","timestamp":1778481388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"alternative-id":["S104084282600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105281","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rewiring immunity: CAR-T cells as a paradigm shift in hematologic oncology","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105281"}}